The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

In a method of producing an optically active -aminocarbonyl compound using a column reactor, a column for a column reactor is charged with asymmetric catalyst particles to form a column reactor. Compounds for a Mannich-type reaction are introduced into the column reactor to be brought into contact with the asymmetric catalyst particles, to thereby convert the compounds to an optically active -aminocarbonyl compound. The preferable asymmetric catalyst particles are resin particles that are prepared from a monomer composition containing a proline derivative monomer having an unsaturated bond and a radical polymerization initiator, and that act as a catalyst for an asymmetric Mannich-type reaction.

In a method of producing an optically active -aminocarbonyl compound using a column reactor, a column for a column reactor is charged with asymmetric catalyst particles to form a column reactor. Compounds for a Mannich-type reaction are introduced into the column reactor to be brought into contact with the asymmetric catalyst particles, to thereby convert the compounds to an optically active -aminocarbonyl compound. The preferable asymmetric catalyst particles are resin particles that are prepared from a monomer composition containing a proline derivative monomer having an unsaturated bond and a radical polymerization initiator, and that act as a catalyst for an asymmetric Mannich-type reaction.

Compounds having Formula I or II, and methods of making and using thereof, are described herein: ##STR00001##

Compounds having Formula I or II, and methods of making and using thereof, are described herein: ##STR00001##

The present invention provides a compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.

The present invention provides a compound represented by the following formula (I): ##STR00001##
wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.